Ursodiol in patients with parenteral nutrition-associated cholestasis

Annals of Pharmacotherapy

Volumn 41, Issue 11, 2007, Pages 1867-1872

  San Luis, Valerie A ^a,b,c   Btaiche, Imad F ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^c HUNTINGTON MEMORIAL HOSPITAL   (United States)

Author keywords

Cholestasis; Parenteral nutrition; Ursodeoxycholic acid; Ursodiol

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; URSODEOXYCHOLIC ACID;

BILE COMPOSITION; BILIRUBIN BLOOD LEVEL; CHOLESTASIS; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HUMAN; LIVER METABOLISM; NONHUMAN; OUTCOMES RESEARCH; PARENTERAL NUTRITION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SHORT BOWEL SYNDROME;

ANIMALS; CHOLAGOGUES AND CHOLERETICS; CHOLESTASIS; HUMANS; PARENTERAL NUTRITION; URSODEOXYCHOLIC ACID;

EID: 35748929963     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K229     Document Type: Review

References (25)

1. Spencer AU, Neaga A, West B, et al. Pediatric short bowel syndrome: redefining predictors of success. Ann Surg 2005;242:403-12.
2. Bishop WP, Haber BA, Lichtman SN, Shneider BL. Another bear market disappointment? Ursodiol for TPN cholestasis. J Pediatr Gastroenterol Nutr 2003;36:422-3.
3. Btaiche IF, Khalidi N. Parenteral nutrition-associated liver complications in children. Pharmacotherapy 2002;22:188-211.
4. Hofmann AF. Pharmacology of ursodeoxycholic acid, an enterohepatic drug. Scand J Gastroenterol 1994;29(suppl 204):1-15.
5. Teitelbaum DH, Tracy TF, Aouthmany MM, et al. Use of cholecystokinin- octapeptide for the prevention of parenteral nutrition-associated cholestasis. Pediatrics 2005;115:1332-40.
6. Spagnuolo MI, Iorio R, Vegnente A, Guarino A. Ursodeoxycholic acid for the treatment of cholestasis in children on long-term total parenteral nutrition: a pilot study. Gastroenterology 1996;111:716-9.
7. De Marco G, Sordino D, Bruzzese E, et al. Early treatment with ursodeoxycholic acid for cholestasis in children on parenteral nutrition because of primary intestinal failure. Aliment Pharmacol Ther 2006;24:387-94.
8. Levine A, Maayan A, Shamir R, Dinari G, Sulkes J, Sirotta L. Parenteral nutrition-associated cholestasis in preterm neonates: evaluation of ursodeoxycholic acid treatment. J Pediatr Endocrinol Metab 1999;12:549-53.
9. Chen C, Tsao P, Chen H, Chou H, Hsieh W, Chang M. Ursodeoxycholic acid (UDCA) therapy in very-low-birth-weight infants with parenteral nutrition-associated cholestasis. J Pediatr 2004;145:317-21.
10. Al-Hatholol K, Al-Madani A, Al-Saif S, Abulaimoun B, Al-Tawil K, ElDemerdash A. Ursodeoxycholic acid therapy for intractable total parenteral nutrition-associated cholestasis in surgical very low birth weight infants. Singapore Med J 2006;47:147-51.
11. Beau P, Labat-Labourdette J, Ingrand P, Beauchant M. Is ursodeoxycholic acid an effective therapy for total parenteral nutrition-related liver disease? J Hepatol 1994;20:240-4.
12. Heubi JE, Wiechmann DA, Creutzinger V, et al. Tauroursodeoxycholic acid (TUDCA) in the prevention of total parenteral nutrition-associated liver disease. J Pediatr 2002;141:237-42.
13. US National Institutes of Health. Randomized study of tauroursodeoxycholic acid in prophylactic therapy of total parenteral nutrition associated cholestasis in infants. www.clinicaltrials.gov/ct/show/NCT00004410? order= 1 (accessed 2007 May 24).
14. Paumgartner G, Beuers U. Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease. Clin Liver Dis 2004; 8:67-81.
15. Hofmann AF. Biliary secretion and excretion in health and disease: current concepts. Ann Hepatol 2007;6:15-27.
16. Kumar D, Tandon RK. Use of ursodeoxycholic acid in liver diseases. J Gastroenterol Hepatol 2001;16:3-14.
17. Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. J Hepatol 2001;35:134-46.
18. Botla R, Spivey JR, Aguilar H, Bronk SF, Gores GJ. Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA cytoprotection. J Pharmacol Exp Ther 1995;272:930-8.
19. Takemoto K, Hodding JH, Kraus DM, eds. Ursodiol. Pediatric dosage handbook. 13th ed. Hudson, OH: Lexi-Comp Inc., 2006:1415-6.
20. Red Book, 2006. Montvale, NJ: Thomson PDR.
21. Nahata MC, Pai VB, Hippie TF. Pediatric drug formulations. 5th ed. Cincinnati, OH: Harvey Whitney Books, 2003:288.
22. Duerksen DR, Van Aerde JE, Gramlich L, et al. Intravenous ursodeoxycholic acid reduces cholestasis in parenterally fed newborn piglets. Gastroenterology 1996;111:1111-7.
23. Gunsar C, Melek M, Karaca I, et al. The biochemical and histopathological effects of ursodeoxycholic acid and metronidazole on total parenteral nutrition-associated hepatic dysfunction: an experimental study. Hepatogastroenterology 2002;49:497-500.
24. Heemskerk J, Sie GH, Van den Neucker AM, Forget P, Heineman E, Ernest van Heurn LW. Extreme short bowel syndrome in a full-term neonate-a case report. J Pediatr Surg 2003;38:1665-6.
25. Lindor KD, Burnes J. Ursodeoxycholic acid for the treatment of home parenteral nutrition-associated cholestasis. Gastroenterology 1991;101: 250-3.